AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

4DMEDICAL LTD

3.480

+0.0200.58%

Volume:1.54M

Turnover:5.34M

Market Cap:2.09B

PE:-10.17

High:3.500

Open:3.420

Low:3.400

Close:3.460

52wk High:7.550

52wk Low:1.400

Shares:601.57M

Float Shares:377.76M

Volume Ratio:0.43

T/O Rate:0.41%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.342

EPS(LYR):-0.342

ROE:-174.43%

ROA:-15.62%

PB:12.30

PE(LYR):-10.17

Loading ...

Overview Company News Filings

Is 4DMedical’s (ASX:4DX) CT:VQ Push and Index Debut Reframing Its Risk‑Reward Profile?

Simply Wall St.

Is 4DMedical’s (ASX:4DX) GSK Imaging Deal a Clue to Its Evolving Business Model?

Simply Wall St.

A Look At 4DMedical’s Valuation After New GlaxoSmithKline Imaging Contract

Simply Wall St.

4DMedical's Year-to-Date Fiscal 2026 Operating Revenue Rises 12% Year on Year

MT Newswires Live

4DMedical Says State Street Becomes Substantial Holder

MT Newswires Live

A Look At 4DMedical’s (ASX:4DX) Valuation After Its New GlaxoSmithKline Lung Imaging Contract

Simply Wall St.

Is 4DMedical's (ASX:4DX) ASX 200 Debut a Turning Point in Its Risk Narrative?

Simply Wall St.

BRIEF-4Dmedical Executes Contract With Glaxosmithkline For Lung Imaging Analytics

4DMedical Secures One-Year Deal With GlaxoSmithKline

MT Newswires Live

Stock Track | 4DMedical Soars 8.22% Intraday on GSK Contract, UK Certification, and ASX 200 Inclusion

4DMedical Ltd - Ct:Vq Receives Ukca Certification for Clinical Use in United Kingdom

THOMSON REUTERS

4DMedical Ltd-GSK Contract, UK Clearance for Ctvq, and ASX 200 Inclusion

THOMSON REUTERS

4DMedical Ltd - Executes Contract With Glaxosmithkline for Lung Imaging Analytics

THOMSON REUTERS

ASX Biggest Losers

MT Newswires Live

S&P Dow Jones Indices: Insignia Financial Limited to Be Removed From the S&P/ASX 200 Index

THOMSON REUTERS

A Look At 4DMedical (ASX:4DX) Valuation After CE Mark Milestone For CT:VQ In Europe

Simply Wall St.

Stock Track | 4DMedical Soars 5.26% Intraday Following EU Regulatory Approval and A$83 Million Capital Raise

EU CT:VQ Approval And A$83m Raise Might Change The Case For Investing In 4DMedical (ASX:4DX)

Simply Wall St.

Assessing 4DMedical (ASX:4DX) Valuation After CE Mark Approval And A$83 Million Equity Raise

Simply Wall St.

4DMedical wins EU CE Mark approval for CT:VQ lung imaging software

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/4DX.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"4DX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"4DX.AU\",,,,,undefined,":{"symbol":"4DX.AU","market":"AU","secType":"STK","nameCN":"4DMEDICAL LTD","latestPrice":3.48,"timestamp":1789020720000,"preClose":3.46,"halted":0,"volume":1543114,"delay":0,"changeRate":0.0057803468208092535,"nameEN":"4DMEDICAL LTD","floatShares":377762864,"shares":601571602,"eps":-0.342118,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"09-10 16:12:00 AEST","open":3.42,"high":3.5,"low":3.4,"amount":5339171,"amplitude":0.028902,"askPrice":3.5,"askSize":14781,"bidPrice":3.48,"bidSize":1027,"shortable":3,"etf":0,"ttmEps":-0.342118,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":3.46,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":0.429432,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"4DX.AU","preClose":3.46,"auctionPrice":3.49,"auctionVolume":139813,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020603559}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"4DX.AU\",,,,,undefined,":{"symbol":"4DX.AU","floatShares":377762864,"roa":"-15.62%","roe":"-174.43%","lyrEps":-0.342118,"volumeRatio":0.429432,"shares":601571602,"dividePrice":0,"high":3.5,"amplitude":0.028902,"preClose":3.46,"low":3.4,"week52Low":1.4,"pbRate":"12.30","psRate":"296.46","week52High":7.55,"institutionHeld":0,"latestPrice":3.48,"committee":-0.870066,"eps":-0.342118,"divideRate":0,"volume":1543114,"delay":0,"ttmEps":-0.342118,"open":3.42,"prevYearClose":3.93,"prevWeekClose":3.6,"prevMonthClose":3.42,"prevQuarterClose":4.53,"fiveDayClose":3.44,"twentyDayClose":3.91,"sixtyDayClose":3.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/4DX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"4DX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"4DX.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634251605","title":"Is 4DMedical’s (ASX:4DX) CT:VQ Push and Index Debut Reframing Its Risk‑Reward Profile?","url":"https://stock-news.laohu8.com/highlight/detail?id=2634251605","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634251605?lang=en_us&edition=fundamental","pubTime":"2026-05-12 07:25","pubTimestamp":1778541936,"startTime":"0","endTime":"0","summary":"In recent trading, 4DMedical has continued to attract attention as investors respond to ongoing operational and regulatory progress, particularly around its CT:VQ respiratory imaging technology and expanded commercial footprint.\nThis momentum has been underpinned by 4DMedical’s entry into the S&P/ASX 200 index and its sizeable recent capital raisings, which have opened the door to greater institutional participation and supported its international expansion plans.\nWe’ll now examine how the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/is-4dmedicals-asx4dx-ctvq-push-and-index-debut-reframing-its","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/is-4dmedicals-asx4dx-ctvq-push-and-index-debut-reframing-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7094","4DX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632960372","title":"Is 4DMedical’s (ASX:4DX) GSK Imaging Deal a Clue to Its Evolving Business Model?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632960372","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632960372?lang=en_us&edition=fundamental","pubTime":"2026-05-03 07:24","pubTimestamp":1777764264,"startTime":"0","endTime":"0","summary":"4DMedical Limited recently announced a one-year contractual engagement, commencing 1 May 2026, to provide its proprietary quantitative lung imaging analytics to GlaxoSmithKline, in association with Flywheel Exchange, in support of pulmonary drug development and clinical research.\nThis agreement with one of the world’s large pharmaceutical companies adds to 4DMedical’s existing biopharma relationships and underlines growing use of its lung imaging platform in clinical trials.\nWe’ll now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/is-4dmedicals-asx4dx-gsk-imaging-deal-a-clue-to-its-evolving","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/is-4dmedicals-asx4dx-gsk-imaging-deal-a-clue-to-its-evolving","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4532","GSK.UK","LU1829250122.USD","BK4588","GSK","4DX.AU","BK7094","GSKH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632097615","title":"A Look At 4DMedical’s Valuation After New GlaxoSmithKline Imaging Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2632097615","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632097615?lang=en_us&edition=fundamental","pubTime":"2026-05-01 14:51","pubTimestamp":1777618302,"startTime":"0","endTime":"0","summary":"Why the new GlaxoSmithKline contract matters for 4DMedical\n4DMedical (ASX:4DX) has drawn fresh attention after securing a one year engagement with GlaxoSmithKline to supply quantitative lung imaging analytics for pulmonary drug development and clinical research, in association with Flywheel Exchange.\nUnder the agreement, starting May 1, 2026, 4DMedical will provide advanced lung imaging biomarkers from its software analytics platform, supporting sensitive, quantitative assessment of lung...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/a-look-at-4dmedicals-valuation-after-new-glaxosmithkline-ima","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/a-look-at-4dmedicals-valuation-after-new-glaxosmithkline-ima","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7094","4DX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631508657","title":"4DMedical's Year-to-Date Fiscal 2026 Operating Revenue Rises 12% Year on Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2631508657","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631508657?lang=en_us&edition=fundamental","pubTime":"2026-04-30 11:49","pubTimestamp":1777520988,"startTime":"0","endTime":"0","summary":"4DMedical  said the operating revenue for year-to-date fiscal 2026 was AU$5 million, up 12% compared to the prior corresponding period, with gross margins exceeding 90%, according to a Thursday Australian bourse filing.It reported operating revenue of AU$4.5 million in the prior-year period, according to a separate filing.Receipts from customers in the fiscal third quarter ended March increased 18% year-over-year to AU$1.4 million, from AU$1.2 million.Underlying software-as-a-service revenue was up 24% year-over-year for the nine months to March, driven by increased penetration across business-to-business software-as-a-service sites and distributors.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7094","4DX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630732252","title":"4DMedical Says State Street Becomes Substantial Holder","url":"https://stock-news.laohu8.com/highlight/detail?id=2630732252","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630732252?lang=en_us&edition=fundamental","pubTime":"2026-04-28 14:27","pubTimestamp":1777357667,"startTime":"0","endTime":"0","summary":"4DMedical (ASX:4DX) said State Street and its subsidiaries have become a substantial holder in the company on April 24 with a stake of 5.01% or 29.6 million shares, according to a Tuesday Australian bourse filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU1894683348.USD","STT","BK4588","IE0034235188.USD","BK4135","IE00B64PRP62.GBP","4DX.AU","IE00BGHQF748.EUR","LU1883839398.USD","LU1894683264.USD","LU0061475181.USD","IE00B3QW5Z07.USD","BK7094"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629585449","title":"A Look At 4DMedical’s (ASX:4DX) Valuation After Its New GlaxoSmithKline Lung Imaging Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2629585449","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629585449?lang=en_us&edition=fundamental","pubTime":"2026-04-24 01:08","pubTimestamp":1776964109,"startTime":"0","endTime":"0","summary":"4DMedical (ASX:4DX) has secured a one-year contract with GlaxoSmithKline, in association with Flywheel Exchange, to supply quantitative lung imaging analytics for pulmonary drug development and clinical research starting May 1, 2026.\nSee our latest analysis for 4DMedical.\nThe GlaxoSmithKline agreement, recent inclusion in the S&P/ASX 200 Index and the upcoming AI & Technology Virtual Investor Conference sit alongside a share price of A$5.27, with a 30 day share price return of 13.82% and a 90...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/a-look-at-4dmedicals-asx4dx-valuation-after-its-new-glaxosmi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/a-look-at-4dmedicals-asx4dx-valuation-after-its-new-glaxosmi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AIPO","AIYY","BK4585","BK4587","BK7094","BK4543","ARTY","BK4588","CHAT","4DX.AU","BK4528","BK4551","BK4023","AI","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629256011","title":"Is 4DMedical's (ASX:4DX) ASX 200 Debut a Turning Point in Its Risk Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2629256011","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629256011?lang=en_us&edition=fundamental","pubTime":"2026-04-22 14:11","pubTimestamp":1776838291,"startTime":"0","endTime":"0","summary":"4DMedical Limited (ASX:4DX) was added to the S&P/ASX 200 Index on 13 April 2026, marking its entry into Australia’s benchmark equities basket.\nThis index inclusion could broaden 4DMedical’s investor base as index-tracking funds and institutional portfolios reassess their exposure to the company.\nWe’ll now examine how 4DMedical’s addition to the S&P/ASX 200 may reshape its investment narrative and longer-term risk profile.\nFind 10 companies with promising cash flow potential yet trading below...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/is-4dmedicals-asx4dx-asx-200-debut-a-turning-point-in-its-ri","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/is-4dmedicals-asx4dx-asx-200-debut-a-turning-point-in-its-ri","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4528","AIPO","BK4587","AI","BK4588","AIYY","AGIX","BK4075","BK4543","BK4551","ARTY","BK4585","BK7094","CHAT","BK4023","4DX.AU","TPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628797243","title":"BRIEF-4Dmedical Executes Contract With Glaxosmithkline For Lung Imaging Analytics","url":"https://stock-news.laohu8.com/highlight/detail?id=2628797243","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628797243?lang=en_us&edition=fundamental","pubTime":"2026-04-20 09:31","pubTimestamp":1776648717,"startTime":"0","endTime":"0","summary":"BRIEF-4Dmedical Executes Contract With Glaxosmithkline For Lung Imaging AnalyticsApril 20  - 4DMedical Ltd 4DX.AX:4DMEDICAL LTD-GSK CONTRACT, UK CLEARANCE FOR CTVQ, AND ASX 200 INCLUSIONCT:VQ RECEIVES UKCA CERTIFICATION FOR CLINICAL USE IN UNITED KINGDOMEXECUTES CONTRACT WITH GLAXOSMITHKLINE FOR LUNG IMAGING ANALYTICSFurther company coverage: 4DX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nTUEQ7CKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0557290698.USD","BK7094","SG9999001176.SGD","SGXZ57979304.SGD","LU1015430645.USD","LU0109981661.USD","LU0575583348.USD","LU1035777561.USD","LU1400636491.USD","LU1202635105.USD","LU0225771236.USD","LU0225284248.USD","LU1302929846.USD","LU1228905037.USD","SG9999013999.USD","4DX.AU","LU1046248800.SGD","LU1983299246.USD","LU0058720904.USD","LU1481599808.USD","LU0306806265.USD","LU1670756490.USD","LU0225283273.USD","BK5011","LU1400636574.HKD","LU1228905540.USD","LU0203347892.USD","LU1645745479.HKD","SG9999001176.USD","LU0985481810.HKD","IE00BQJZX424.USD","GSK.UK","LU0289739699.SGD","LU0321505868.SGD","LU0306807586.USD","LU1064927863.SGD","LU0971552673.USD","LU1400636657.SGD","LU1309081286.SGD","LU1487256676.USD","LU0203345920.USD","LU1481600234.SGD","LU0161305163.EUR","LU0211331839.USD","LU0545562505.USD","LU1098665638.USD","IE0034235071.USD","IE00BWDBJ516.SGD","LU0971552830.HKD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628679753","title":"4DMedical Secures One-Year Deal With GlaxoSmithKline","url":"https://stock-news.laohu8.com/highlight/detail?id=2628679753","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628679753?lang=en_us&edition=fundamental","pubTime":"2026-04-20 09:16","pubTimestamp":1776647790,"startTime":"0","endTime":"0","summary":"4DMedical (ASX:4DX) secured a one-year contract with GlaxoSmithKline, in collaboration with imaging data platform Flywheel Exchange, to provide its quantitative lung imaging analytics from May to supp","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["4DX.AU","BK7094"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144016744","title":"Stock Track | 4DMedical Soars 8.22% Intraday on GSK Contract, UK Certification, and ASX 200 Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=1144016744","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144016744?lang=en_us&edition=fundamental","pubTime":"2026-04-20 08:03","pubTimestamp":1776643397,"startTime":"0","endTime":"0","summary":"4DMedical Ltd's stock surged 8.22% during intraday trading on Monday, marking a significant upward movement for the medical imaging technology company.The sharp rise appears to be driven by multiple...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["4DX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628948417","title":"4DMedical Ltd - Ct:Vq Receives Ukca Certification for Clinical Use in United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2628948417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628948417?lang=en_us&edition=fundamental","pubTime":"2026-04-20 07:46","pubTimestamp":1776642406,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nTUEQ7CKJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7094","4DX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628815794","title":"4DMedical Ltd-GSK Contract, UK Clearance for Ctvq, and ASX 200 Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2628815794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628815794?lang=en_us&edition=fundamental","pubTime":"2026-04-20 07:46","pubTimestamp":1776642406,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nTUEQ7CKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["4DX.AU","BK7094"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628794846","title":"4DMedical Ltd - Executes Contract With Glaxosmithkline for Lung Imaging Analytics","url":"https://stock-news.laohu8.com/highlight/detail?id=2628794846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628794846?lang=en_us&edition=fundamental","pubTime":"2026-04-20 07:46","pubTimestamp":1776642406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nTUEQ7CKJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1400636657.SGD","LU0971552673.USD","LU1481599808.USD","LU0225771236.USD","SG9999013999.USD","BK5011","SG9999001176.SGD","LU1015430645.USD","LU0225284248.USD","SGXZ57979304.SGD","SG9999001176.USD","LU0225283273.USD","BK7094","LU1098665638.USD","LU0971552830.HKD","LU1202635105.USD","LU1228905540.USD","LU0211331839.USD","LU0289739699.SGD","LU0321505439.SGD","GSK.UK","LU1046248800.SGD","LU0058720904.USD","IE00BQJZX424.USD","LU0203347892.USD","LU0545562505.USD","LU1400636574.HKD","LU0557290698.USD","LU0306806265.USD","LU0321505868.SGD","LU1670756490.USD","LU1645745479.HKD","LU0985481810.HKD","LU1302929846.USD","LU0575583348.USD","LU1064927863.SGD","IE00B3T34201.USD","LU1309081286.SGD","LU1035777561.USD","LU1481600234.SGD","LU1400636491.USD","4DX.AU","LU0109981661.USD","LU1228905037.USD","LU0306807586.USD","LU0161305163.EUR","LU1983299246.USD","LU0203345920.USD","IE00BWDBJ516.SGD","IE0034235071.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628229373","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2628229373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628229373?lang=en_us&edition=fundamental","pubTime":"2026-04-17 10:44","pubTimestamp":1776393850,"startTime":"0","endTime":"0","summary":"Here are the seven ASX-listed companies with the biggest losses on Friday.4D Medical : -5%, AU$6.08Evolution Mining : -4%, AU$13.30Whitehaven Coal : -3%, AU$8.13Alcoa : -3%, AU$96.50Westgold Resources : -3%, AU$6.25New Hope : -2%, AU$5.33Capricorn Metals : -2%, AU$11.53","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMM.AU","AA","BK7083","WHC.AU","BK4585","BK7081","BK7506","BK7507","BK4588","WGX.AU","BK7104","LU2543165471.USD","NHC.AU","BK4153","BK7094","AAI.AU","EVN.AU","4DX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627487607","title":"S&P Dow Jones Indices: Insignia Financial Limited to Be Removed From the S&P/ASX 200 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2627487607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627487607?lang=en_us&edition=fundamental","pubTime":"2026-04-13 15:12","pubTimestamp":1776064322,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUE8QC7X3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["4DX.AU","BK7062","IFL.AU","BK7094"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626243201","title":"A Look At 4DMedical (ASX:4DX) Valuation After CE Mark Milestone For CT:VQ In Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2626243201","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626243201?lang=en_us&edition=fundamental","pubTime":"2026-04-11 22:20","pubTimestamp":1775917215,"startTime":"0","endTime":"0","summary":"4DMedical (ASX:4DX) has attracted investor attention after its CT:VQ imaging technology secured CE Mark certification for commercial use in the European Union, with a rapid regional rollout now planned.\nSee our latest analysis for 4DMedical.\nInvestors have reacted strongly to the CE Mark news, with the A$6.80 share price reflecting a 55.25% 1 month share price return and a very large 1 year total shareholder return. This suggests momentum has been building rather than fading.\nIf CT based lung...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/a-look-at-4dmedical-asx4dx-valuation-after-ce-mark-milestone","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/a-look-at-4dmedical-asx4dx-valuation-after-ce-mark-milestone","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7094","CE","BK4109","BK4585","BK4588","4DX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183729520","title":"Stock Track | 4DMedical Soars 5.26% Intraday Following EU Regulatory Approval and A$83 Million Capital Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=1183729520","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183729520?lang=en_us&edition=fundamental","pubTime":"2026-04-08 08:08","pubTimestamp":1775606926,"startTime":"0","endTime":"0","summary":"4DMedical Limited's stock soared 5.26% during intraday trading on Wednesday, following two significant positive developments for the medical imaging company.The surge comes after 4DMedical announced...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["4DX.AU"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2625795270","title":"EU CT:VQ Approval And A$83m Raise Might Change The Case For Investing In 4DMedical (ASX:4DX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625795270","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625795270?lang=en_us&edition=fundamental","pubTime":"2026-04-07 23:17","pubTimestamp":1775575026,"startTime":"0","endTime":"0","summary":"4DMedical Limited recently completed an A$83,000,002 follow-on equity offering at A$5.90 per share, shortly after announcing that its CT:VQ imaging technology had received CE Mark certification for commercial use across the European Union.\nThe CE Mark for CT:VQ gives 4DMedical access to one of the world’s largest respiratory imaging markets, leveraging existing CT infrastructure without needing radiotracers or specialised nuclear medicine facilities.\nWe’ll now examine how EU commercial...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/eu-ctvq-approval-and-a83m-raise-might-change-the-case-for-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/eu-ctvq-approval-and-a83m-raise-might-change-the-case-for-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["4DX.AU","BK4156","BK7094"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624948036","title":"Assessing 4DMedical (ASX:4DX) Valuation After CE Mark Approval And A$83 Million Equity Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2624948036","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624948036?lang=en_us&edition=fundamental","pubTime":"2026-04-04 14:27","pubTimestamp":1775284045,"startTime":"0","endTime":"0","summary":"Why the CE Mark and equity raise matter for 4DMedical\nThe trigger for 4DMedical (ASX:4DX) is the CE Mark approval for its CT:VQ imaging technology, which opens commercial use across the European Union and highlights a new phase for the company’s respiratory imaging ambitions.\nThis certification arrives alongside an A$83.0 million follow-on equity offering at A$5.90 per share, suggesting 4DMedical is pairing European market access with fresh capital to support CT:VQ deployment and broader...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-ce-mark-approval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-ce-mark-approval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EQR","BK7094","BK4588","BK4215","CE","BK4109","BK4585","4DX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623399322","title":"4DMedical wins EU CE Mark approval for CT:VQ lung imaging software","url":"https://stock-news.laohu8.com/highlight/detail?id=2623399322","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623399322?lang=en_us&edition=fundamental","pubTime":"2026-03-30 14:20","pubTimestamp":1774851639,"startTime":"0","endTime":"0","summary":"4DMedical received CE Mark certification for CT:VQ, clearing commercial sales across European Union.Company also secured AUD 83 million private placement to fund growth initiatives, including European rollout of CT:VQ.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4DMedical Ltd. published the original content used to generate this news brief via PR Newswire  on March 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL4WPpQP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7094","4DX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":98,"code":"91000000","status":"200"}]}}